888 reiterated their reiterates rating on shares of Vaxcyte (NASDAQ:PCVX – Get Rating) in a research note published on Tuesday, Benzinga reports.
PCVX has been the topic of a number of other research reports. Bank of America lifted their target price on Vaxcyte from $63.00 to $68.00 in a research report on Monday, April 17th. TD Cowen began coverage on Vaxcyte in a research report on Tuesday, April 18th. They issued an outperform rating on the stock. Needham & Company LLC reissued a buy rating and issued a $58.00 target price on shares of Vaxcyte in a research report on Tuesday, February 28th. Finally, Guggenheim dropped their target price on Vaxcyte from $66.00 to $65.00 and set a buy rating on the stock in a research report on Tuesday, February 28th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, Vaxcyte presently has an average rating of Buy and an average price target of $65.00.
Vaxcyte Price Performance
NASDAQ:PCVX opened at $53.31 on Tuesday. Vaxcyte has a fifty-two week low of $17.44 and a fifty-two week high of $54.84. The stock has a market capitalization of $4.30 billion, a PE ratio of -15.50 and a beta of 0.97. The business’s 50-day simple moving average is $40.85 and its 200-day simple moving average is $43.11.
Institutional Inflows and Outflows
Several institutional investors have recently made changes to their positions in the stock. RA Capital Management L.P. increased its position in shares of Vaxcyte by 27.9% during the 4th quarter. RA Capital Management L.P. now owns 5,857,459 shares of the company’s stock worth $280,865,000 after purchasing an additional 1,276,256 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Vaxcyte by 12.5% during the 3rd quarter. Vanguard Group Inc. now owns 4,452,145 shares of the company’s stock worth $106,851,000 after acquiring an additional 496,227 shares during the period. BlackRock Inc. boosted its stake in shares of Vaxcyte by 6.7% during the 3rd quarter. BlackRock Inc. now owns 3,492,321 shares of the company’s stock worth $83,817,000 after acquiring an additional 220,691 shares during the period. State Street Corp boosted its stake in shares of Vaxcyte by 7.4% during the 3rd quarter. State Street Corp now owns 1,993,036 shares of the company’s stock worth $47,833,000 after acquiring an additional 137,392 shares during the period. Finally, Carlyle Group Inc. bought a new position in shares of Vaxcyte during the 1st quarter worth approximately $72,080,000. Institutional investors and hedge funds own 71.50% of the company’s stock.
Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia.
- Get a free copy of the StockNews.com research report on Vaxcyte (PCVX)
- How to Buy Southwest Airlines Stock
- Lucid Group Bottomed, But The Outlook Remains Cloudy
- Shoals Technology is an EV and Solar Play Just Getting Started
- Under Armour May Have Just Bottomed
- Skyworks Solutions: Another Crack in the Consumer Outlook
Receive News & Ratings for Vaxcyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxcyte and related companies with MarketBeat.com's FREE daily email newsletter.